NO20055884L - Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt - Google Patents

Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt

Info

Publication number
NO20055884L
NO20055884L NO20055884A NO20055884A NO20055884L NO 20055884 L NO20055884 L NO 20055884L NO 20055884 A NO20055884 A NO 20055884A NO 20055884 A NO20055884 A NO 20055884A NO 20055884 L NO20055884 L NO 20055884L
Authority
NO
Norway
Prior art keywords
patient
obesity
overweight
schizophrenia
asenanine
Prior art date
Application number
NO20055884A
Other languages
English (en)
Norwegian (no)
Inventor
Jeroen Alphons Dorothe Tonnaer
Original Assignee
Organon Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Ireland Ltd filed Critical Organon Ireland Ltd
Publication of NO20055884L publication Critical patent/NO20055884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20055884A 2003-06-12 2005-12-12 Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt NO20055884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101721 2003-06-12
PCT/EP2004/051069 WO2004110437A1 (en) 2003-06-12 2004-06-09 Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

Publications (1)

Publication Number Publication Date
NO20055884L true NO20055884L (no) 2006-01-03

Family

ID=33547705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055884A NO20055884L (no) 2003-06-12 2005-12-12 Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt

Country Status (24)

Country Link
US (1) US20060128688A1 (da)
EP (1) EP1635820B1 (da)
JP (1) JP2006527238A (da)
KR (1) KR20060020664A (da)
CN (1) CN1816335A (da)
AR (1) AR044675A1 (da)
AT (1) ATE395914T1 (da)
AU (1) AU2004246820B2 (da)
BR (1) BRPI0411237A (da)
CA (1) CA2528365A1 (da)
CY (1) CY1110366T1 (da)
DE (1) DE602004013966D1 (da)
DK (1) DK1635820T3 (da)
ES (1) ES2305829T3 (da)
IL (1) IL172397A (da)
NO (1) NO20055884L (da)
NZ (1) NZ544018A (da)
PL (1) PL1635820T3 (da)
PT (1) PT1635820E (da)
RU (1) RU2352336C2 (da)
SI (1) SI1635820T1 (da)
TW (1) TWI327915B (da)
WO (1) WO2004110437A1 (da)
ZA (1) ZA200509904B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006000080T2 (de) * 2005-04-07 2008-05-15 N.V. Organon Kristallform von Asenapinmaleat
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4099224B2 (ja) * 1994-03-02 2008-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン 舌下又はバッカル医薬組成物
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
US20060128688A1 (en) 2006-06-15
EP1635820A1 (en) 2006-03-22
ZA200509904B (en) 2006-12-27
PT1635820E (pt) 2008-06-17
ES2305829T3 (es) 2008-11-01
SI1635820T1 (sl) 2008-08-31
BRPI0411237A (pt) 2006-07-11
PL1635820T3 (pl) 2008-10-31
KR20060020664A (ko) 2006-03-06
HK1084894A1 (en) 2006-08-11
ATE395914T1 (de) 2008-06-15
DK1635820T3 (da) 2008-09-08
DE602004013966D1 (de) 2008-07-03
EP1635820B1 (en) 2008-05-21
AU2004246820A1 (en) 2004-12-23
CY1110366T1 (el) 2014-04-09
TW200501946A (en) 2005-01-16
CA2528365A1 (en) 2004-12-23
IL172397A0 (en) 2006-04-10
CN1816335A (zh) 2006-08-09
IL172397A (en) 2010-06-16
RU2006101061A (ru) 2006-07-27
TWI327915B (en) 2010-08-01
AU2004246820B2 (en) 2009-10-01
NZ544018A (en) 2008-07-31
JP2006527238A (ja) 2006-11-30
AR044675A1 (es) 2005-09-21
RU2352336C2 (ru) 2009-04-20
WO2004110437A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
MA32611B1 (fr) Procedes de traitement de la thalassemie
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA200971053A1 (ru) Способы лечения кожных язв
WO2009068659A3 (en) Novel disease treatment by predicting drug association
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20083004L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
DK1973541T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer
EA201270449A1 (ru) Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний
WO2010148121A3 (en) Benzothiazole derivatives
KR20120128644A (ko) 질환의 치료에 사용하기 위한 화합물
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application